Good news! What a positive side effect!
Background: "Just 3 percent to 5 percent of those with a past alcohol abuse disorder reported using the [anti-abuse] drugs in a recent national survey, and only 10 percent of those seeking treatment have received the approved drugs."
"Nearly half of drinkers who take GLP-1 medications have reported declines in consumption, with the effect higher among those at risk of unhealthy alcohol use, a new Harvard study shows. ..."
"Approximately 178 000 US residents die from excessive alcohol use each year,1 and public health messaging increasingly emphasizes that any amount of drinking increases health risks.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are US Food and Drug Administration–approved for type 2 diabetes and obesity, and their use has grown dramatically in recent years.
Emerging evidence, including early-phase randomized trials, suggests that GLP-1 RAs may also reduce alcohol use, likely through effects on brain pathways involved in craving and reward processing. However, patient perspectives on the impact of GLP-1 RAs on alcohol use have not, to our knowledge, been captured systematically.
Through a nationally representative survey of US adults, we estimated the population prevalence of patient-reported reductions in alcohol use following GLP-1 RA initiation and assessed public awareness of the potential impact of GLP-1 RAs on alcohol use."
No comments:
Post a Comment